Dermatomyositis can affect both physical strength and quality of life, yet treatment options specifically developed for the condition have remained limited. Lisraya (brepocitinib) introduces a new oral treatment option for adults living with this rare autoimmune disease.
Its approval represents an important step in the development of targeted therapies for dermatomyositis and adds a new option to the treatment landscape.
For clinical trial and first-to-file teams working in autoimmune and rare disease research, monitoring Lisraya’s adoption, exclusivity, and availability could become increasingly relevant.
